Oaktree Acquisition Corp III Life Sciences - Class A

Research Oaktree Acquisition Corp III Life Sciences - Class A (OACC) on Bullrun: market cap USD 265.00M, P/E 39.2. Explore financials, valuation history, model signals, and stock context.

Key Metrics

Valuation Snapshot

latest market cap is USD 265.00M; P/E is 39.2.

Peer valuation comparison

Latest P/E is 39.23x versus a Financial Services sector median of 13.84x (183.5% above).

Latest P/E is 39.23x versus a United States median of 24.87x (57.8% above).

Five-year financial history

YearRevenueNet incomeFree cash flowGross marginDiluted EPSCashTotal debtEquity
FY2025USD 0USD 7.29M-USD 422.08Kn/a0.53USD 1.43MUSD 11.82K-USD 6.77M

Valuation history

YearSnapshot dateMarket capP/EDividend yieldAnnual dividend/share
20262026-08-25USD 265.00M39.2n/an/a
20252025-12-31USD 260.09M35.3n/an/a
20242024-12-31USD 244.84M199.2n/an/a

About Oaktree Acquisition Corp III Life Sciences - Class A

Oaktree Acquisition Corp. III Life Sciences does not have significant operations. The company focuses on effecting a merger, share exchange, asset acquisition, share purchase, reorganization, or similar business combination with one or more businesses or entities. It intends to target companies in the biopharmaceutical, medical devices, diagnostics, and specialized healthcare services sectors in North America and Europe. The company was founded in 1995 and is headquartered in Los Angeles, California.

Related stock research

Other Financial Services stocks

Frequently asked questions

What is Oaktree Acquisition Corp III Life Sciences - Class A's market cap?

Oaktree Acquisition Corp III Life Sciences - Class A's market capitalization is USD 265.00M.

What is Oaktree Acquisition Corp III Life Sciences - Class A's P/E ratio?

Oaktree Acquisition Corp III Life Sciences - Class A's price-to-earnings (P/E) ratio is 39.2.

What does Oaktree Acquisition Corp III Life Sciences - Class A do?

Oaktree Acquisition Corp. III Life Sciences does not have significant operations. The company focuses on effecting a merger, share exchange, asset acquisition, share purchase, reorganization, or similar business combination with one or more businesses or entities. It intends to target companies in the biopharmaceutical, medical devices, diagnostics, and specialized healthcare services sectors in North America and Europe. The company was founded in 1995 and is headquartered in Los Angeles, California.